Compare CARS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | PRME |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.3M | 666.1M |
| IPO Year | 2017 | 2022 |
| Metric | CARS | PRME |
|---|---|---|
| Price | $12.45 | $3.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $17.70 | $6.42 |
| AVG Volume (30 Days) | 896.2K | ★ 3.8M |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $719,767,000.00 | $5,977,000.00 |
| Revenue This Year | $2.49 | $111.80 |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $27.07 | ★ N/A |
| Revenue Growth | 0.20 | ★ 647.13 |
| 52 Week Low | $9.56 | $1.11 |
| 52 Week High | $19.00 | $6.94 |
| Indicator | CARS | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 39.61 |
| Support Level | $11.85 | $3.61 |
| Resistance Level | $13.69 | $4.12 |
| Average True Range (ATR) | 0.41 | 0.28 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 33.97 | 0.53 |
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.